Cingulate Inc (CING NASDAQ) stock market data APIs
$3.8718
0.05(1.3%)
as of September 15, 2025
Try our APIs with
free plan!
Cingulate Inc Financial Data Overview
Price chart is built with
Anychart
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Prev. Close
3.8718
Open
3.917
High
3.9813
Low
3.8478
52 wk Range
3.02-6.01
Market Cap
21 379 K
P/E Ratio
0.0293
Shares Outstanding
5 413 K
EPS
-1.09
Beta
-0.77
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cingulate Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cingulate Inc data using free add-ons & libraries
Get Cingulate Inc Fundamental Data
Cingulate Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -17 208 596
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-19
- EPS/Forecast: -0.93
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cingulate Inc News
New
Ascendiant Capital raises Cingulate stock price target to $62 from $61
Investing.com - Ascendiant Capital has raised its price target on Cingulate (NASDAQ:CING) to $62.00 from $61.00 while maintaining a Buy rating on the stock. With shares currently trading at $3.99, t...
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, ...
Cingulate places CEO Schaffer on administrative leave
* The Board of Directors of Cingulate (NASDAQ:CING [https://seekingalpha.com/symbol/CING]) announced on Friday that it has placed chairman and chief executive officer, Shane J. Schaffer on administ...
Cingulate Provides Management Team Update
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Boa...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
